A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
At a glance
- Drugs NKTR 181 (Primary)
- Indications Back pain; Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Acronyms SUMMIT-07
- Sponsors Nektar Therapeutics
- 01 Mar 2018 According to a Nektar Therapeutics media release, data from this study will be presented at American Association for Cancer Research (AACR) Annual Meeting 2018 in first half of 2018.
- 01 Mar 2018 Results published in the Nektar Therapeutics Media Release.
- 06 Sep 2017 According to a Nektar Therapeutics media release, data from the study has been presented at the 2017 PAINWeek Conference.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History